United States: OIG Gives Stamp Of Approval For Innovative Warranty Program

The Office of Inspector General (OIG) recently approved a medical device manufacturer's innovative proposed warranty program, under which the company would provide a refund to the hospital at which a patient underwent joint replacement surgery using the company's knee or hip implant and related products, if the patient was readmitted within 90 days because of a surgical site infection or need for implant replacement surgery. Advisory Opinion No. 18-10 concluded that although the proposed arrangement did not meet the specific criteria of the warranty safe harbor to the Anti-Kickback Statute (AKS), it nonetheless posed an acceptably low risk of fraud and abuse.

This is the latest in a series of recent signals from OIG of its willingness to support innovative risk-sharing models and value-based arrangements, even when the strict requirements of a potentially applicable safe harbor are not technically met.

The warranty program

The warranty program related to a Product Suite consisting of (1) a total knee or total hip implant, (2) a wound therapy system, and (3) an antimicrobial dressing. The company proposed to give a refund to hospitals, in the amount of the aggregate purchase price of the Product Suite, if:

  • All three products were used together on the patient in a manner consistent with their instructions for use and other labeling.
  • The patient was readmitted within 90 days as an inpatient to the same hospital where the initial surgery was performed because of a subsequent surgical site infection or need for a surgical procedure to replace the implanted knee or hip system.
  • The readmission resulted from a failure of one of the three products to perform as expected (to which the hospital must certify).

The refund would include the full aggregate purchase price of all three products in the Product Suite, regardless of which, or how many, failed. The program also would not take into account the patient's insurance status or, if covered, the particular third-party payor. The proposed warranty program included a variety of other features and safeguards, further discussed below with respect to OIG's analysis.

OIG's analysis

The warranty safe harbor does not apply to the proposed warranty program

The warranty safe harbor to the AKS, codified at 42 C.F.R. § 1001.952(g), permits refunds of the cost of warranted items, so long as certain requirements are satisfied by both the manufacturer (42 C.F.R. § 1001.952(g)(3)–(4)) and the buyer (42 C.F.R. § 1001.952(g)(1)–(2)). Those conditions require the full and accurate reporting of the price reduction at the time of the sale (or if the amount is not known at the time of the sale, the reporting of the existence of the program at the time of the sale and provision to the buyer of documentation at the time the price reduction becomes known), and the provision of notice to the buyer of additional reporting obligations potentially applicable to them.

However, OIG determined that the warranty safe harbor did not protect this proposed arrangement because it concluded that the safe harbor does not apply to bundled items. OIG stated that the safe harbor text referring to a payment under a warranty provided by a manufacturer or supplier of "an item" did not contemplate a bundle of items. OIG additionally contrasted the warranty safe harbor with the discount safe harbor, 42 C.F.R. § 1001.952(h), which permits discounts on bundled items when the goods or services are reimbursed by the same Federal health care program using same payment methodology and the discounts are disclosed to the program and reflected where and as appropriate to the reimbursement methodology. While OIG's reading of the warranty safe harbor arguably applies limitations not clearly apparent from the safe harbor text, OIG concluded the warranty safe harbor does not apply to bundled items and therefore did not protect this arrangement.

The proposed warranty program nonetheless does not violate the AKS

However, proposed arrangements that do not squarely fit into an existing safe harbor are not per se illegal. Rather, OIG evaluates such arrangements on a case-by-case basis based on the totality of the facts and circumstances. This is the analysis OIG undertook of the company's proposed warranty program, ultimately concluding that the arrangement poses a sufficiently low risk of fraud and abuse under the AKS. OIG offered five reasons for this conclusion:

  1. The products are not separately reimbursable. Rather, under the Medicare Inpatient Prospective Payment System, they are reimbursed through one bundled Medicare severity diagnosis-related group ("MS-DRG") payment for all the items and services a hospital furnishes in connection with an inpatient stay for joint replacement surgery. The program would not require the patient to continue using the company's products (for example, wound therapy system or antimicrobial dressing) after discharge. The hospital's inability to bill for each product individually reduces the risk of overutilization or inappropriate use of the products, thus diminishing OIG's concerns that the warranty program would lead to increased costs to Medicare. OIG stated that the requester certified that Medicare Advantage plans also make bundled payments for inpatient joint replacement surgeries. While "in certain infrequent instances, some of the Products may be separately reimbursable under a state's Medicaid program[,] Requestor stated that Medicaid represents a very small portion of Requestor's business."
  2. The company would still meet all the obligations of a seller under the warranty safe harbor, including reporting the existence of the warranty program fully and accurately on the invoice or statement at the time of purchase, reporting the refund amount when it becomes known, and informing the hospital of its reporting obligations with respect to the refund and the necessity of disclosing information related to the refund to the U.S. Department of Health and Human Services ("HHS") upon request. Because the company would put hospitals on notice of their obligation to appropriately report any refund they obtained through the warranty program, the program has the result both of increasing transparency and diminishing the concern of increased costs to Federal health care programs.
  3. Physicians remain responsible for determining the medical necessity and clinical appropriateness of each of the three products for any particular patient. In fact, hospitals would be required to certify this fact as a condition of participation in the warranty program, in addition to a certification that the products were used in a manner consistent with instructions for use and other labeling. These requirements, OIG found, decreased the risk that the products would be used in a clinically inappropriate or medically unnecessary manner.
  4. Both patients and Federal health care programs would likely benefit. The purpose of the warranty program is to reduce the incidence of readmissions following joint replacement surgery because of either a surgical site infection or a revision to the implanted hip or knee system. The hospital, which is in the best position to access information about the patient's medical records and has medically trained professionals on staff, would be responsible for assessing whether the warranty program's requirements would be satisfied with respect to any particular patient. The products, when used in combination, are designed to reduce the incidence of infection-related readmissions and revisions. OIG thus concluded that the warranty program was reasonably related to use of the Product Suite and that, in the absence of other contradictory information, a hospital could reasonably conclude that a subsequent infection or revision resulted from the failure of the Product Suite to perform as expected. Under these circumstances, OIG was "reluctant to chill innovative and potentially beneficial arrangements."
  5. Hospitals retain flexibility to use other manufacturers' products. The warranty program contained no exclusivity requirements, quotas, minimums, or other eligibility criteria related to the volume or value of referrals. Nor would hospitals be compelled to encourage or require physicians to use the company's products. In short, the program would not (1) impede hospitals' ability to make purchasing decisions that result in both the best value and the best clinical outcomes for their patients, or (2) require coercive communications from a hospital to physicians regarding the company's products.

Based on these factors, even though it determined that the arrangement does not fit within the warranty safe harbor, OIG concluded that it nonetheless posed a sufficiently low risk of fraud and abuse under the AKS.

Key takeaways

OIG's approval of this innovative warranty program draws further attention to value-based contracting, a hot topic of late. Because many pioneering risk-sharing models likely do not technically comply with the strict requirements of an AKS safe harbor, manufacturers and providers alike may be reluctant to wade into the gray area outside the safety of that protection. Now, however, OIG has blessed an innovative risk-sharing business model, providing at least some guidance as to how OIG would approach similar models. (Of course, OIG is careful to remind the public that only the requestor may rely on this particular Advisory Opinion, but these Advisory Opinions nonetheless provide a window into how the OIG is likely to analyze similar arrangements.)

OIG's approval of this warranty program is consistent with several other recent signals from OIG indicating its increasing interest in value-based arrangements, including last year's Advisory Opinion 17-03, which approved a pharmaceutical manufacturer's proposal to offer customers replacements for certain spoiled products that could no longer be administered to patients, as well as OIG's August 27, 2018, Request For Information (RFI) seeking input from the public on how to foster arrangements that would promote care coordination and the delivery of value-based care. (See our prior coverage of this RFI here.) For several years now, industry groups such as the Advanced Medical Technology Manufacturers Association ("AdvaMed"), as well as multiple individual manufacturers and providers, have responded to the OIG's annual safe harbor solicitation by requesting new or revised safe harbors to permit value-based or outcomes-based arrangements. Companies interested in value-based or risk-sharing models should strongly consider submitting comments in response to the RFI (comments are due by October 26, 2018).

Client Alert 2018-197

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions